Volume 33, No 5, May 2023

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 33 Issue 5, May 2023: 335-336

RESEARCH HIGHLIGHTS

Mitochondrial PD-L1 modulates cancer immunotherapy

Xiaoming Dai^1,† , Jing Liu^1,† , Wenyi Wei^1,*

¹Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
^†These authors contributed equally: Xiaoming Dai, Jing Liu
Correspondence: Wenyi Wei(wwei2@bidmc.harvard.edu)

The expression and subcellular localization of immune checkpoint protein PD-L1 have been implicated to play an important role in cancer immunotherapy. In a recent paper published in Cell Research, Xie et al. report that promoting mitochondrial distribution of PD-L1 through targeting the ATAD3A-PINK1-mitophagy axis is a promising strategy to overcome chemoimmunotherapy resistance.

https://doi.org/10.1038/s41422-023-00777-4

FULL TEXT | PDF

Browse 242